AMLSG-11-08 - Dasatinib Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel?) Following Induction and Consolidation Th
{"Image DocumentName": "Additional Induction cycle", "Image ImageDescription": "AMLSG Dasatinib. Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel?) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) - AMLSG Screnning. for. CBF. Consolidation. Maintenance. Induction. Einschlusskriterien. CBF \u2013 AML. No prior chemotherapy for leukemia except hydroxyurea up to 5 days during the diagnostic screening phase. Ausschlusskriterien. Pulmonary edema and/or pleural/pericardial effusion within 14 days of Day 1. Maintenance. Therapy. with. Dasatinib. DNR+ARA-C. HDAC. HDAC. HDAC. HDAC. Dasatinib. CR. Dasatinib. Dasatinib. Dasatinib. Dasatinib. CR. No CR or Cri. On day 21-28; Additional Induction cycle. CR. DNR+ARA-C. Dasatinib. RD off study. CBF Core binding factor, DNR Daunorubicin, ARA-C Cytarabine, CR complete remission, RD refractory disease. Rekrutierung: Beginn Ende Patientenzahl: 57 Ansprechpartner: PI Prof. Walter Fiedler SI Dr. Maxim Kebenko et al. Intern SK Ramona Michallik Entit\u00e4ten.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}